43 results
DEFA14A
EX-99.2
AGIO
Agios Pharmaceuticals Inc
21 Dec 20
Additional proxy soliciting materials
7:10am
and stakeholders 2 Thoughtfully pursue capital markets independence while right-sizing the company 3 Move forward with a singular focus on genetically defined … to shareholders; residual proceeds will be retained to achieve capital market independence to fund the company through major catalysts
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
21 Dec 20
Regulation FD Disclosure
7:04am
and stakeholders 2 Thoughtfully pursue capital markets independence while right-sizing the company 3 Move forward with a singular focus on genetically defined … to shareholders; residual proceeds will be retained to achieve capital market independence to fund the company through major catalysts
DEF 14A
AGIO
Agios Pharmaceuticals Inc
7 Apr 14
Definitive proxy
12:00am
OF DIRECTORS
CORPORATE GOVERNANCE
General
Director Independence
Board Leadership Structure
The Board’s Role in Risk Oversight
Board of Directors Meetings … request to Agios Pharmaceuticals, Inc., 38 Sidney Street, 2nd Floor, Cambridge, MA 02139.
Director Independence
Rule 5605 of the NASDAQ Listing Rules
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
3 Dec 18
Other Events
4:03pm
characterized by a low rate of febrile neutropenia and infections. In addition, transfusion independence was observed across response categories … 77.8%, 66.7% and 59.5%, respectively.
Transfusion independence, defined as an absence of transfusions for at least 56 consecutive days on treatment
DEFA14A
dje1g sg7d03mv9q
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
j20uzghc04
23 Dec 20
Additional proxy soliciting materials
4:52pm
DEFA14A
01ywv
21 Dec 20
Additional proxy soliciting materials
5:23pm
8-K
EX-99.1
4noclempqp vtx8
21 Dec 20
Regulation FD Disclosure
7:04am
DEFA14A
EX-99.1
jiwg 330ekzw
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
0mco l4zppy
20 Jul 18
FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients
11:21am
8-K
EX-99.1
j2fnyb602t4pp1blalt
3 Jun 19
Other Events
4:02pm
S-1
EX-4.2
eqmlt yrkz
10 Jun 13
IPO registration
12:00am
8-K
EX-99.2
9hc10yi
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
424B4
mks6a04rksuuxg8l05
24 Jul 13
Prospectus supplement with pricing info
12:00am